On September 13, 2023, DalCor Pharmaceuticals announced the closing of a $80 million Series D financing round. This funding will be utilized towards conducting the Dal-GenE-2 confirmatory trial in North America through a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).

The round was backed by Fonds de Developpement Economique managed by Investissement Quebec and Fonds Propres d'Investissement Quebec. Existing investors, such as Andes Growth, TB Pharma, Fonds de solidarite FTQ and CTI Life Sciences, also participated.

DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease. Its purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine in cardiovascular disease that specifically targets patients with the AA genotype at rs1967309 location in the ADCY9 gene (ADCY9 AA genotype).

Osler, Hoskin & Harcourt LLP advised DalCor Pharmaceuticals with a team consisting of Shahir Guindi, Sophie Amyot, Matthew Oliver, Marisa Corona, Joshua Blatt and Asma Berrak (Corporate).